Recommendation of the President – Krazati (adagrabin)

On 27 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 12/2026 on the reimbursement of the medicinal product Krazati (adagrabin) under the B.6 drug program “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication in Public Information Bulletin (BIP) >>